Plus a publication showing biopharma companies are investing a truly staggering sum -- nearly $300 billion -- into R&D each year
Plus a link to a nice explainer on health care's toxic trio: accumulators, maximizers, and AFPs
Plus a must-read survey of payers on how they intend to squeeze formularies and boost UM once IRA price controls are in place
And more on an Avalere study on the intersection between 340B and PBMs
Plus an Avalere study shows how PBMs have entwined themselves into the 340B program
Plus some thoughts on a STAT piece suggesting Mark Cuban won't have much impact on drug prices
Plus a 340B 'Viewpoint' in JAMA Health Forum that's worth your time
Plus a 340B hospital system that's getting into the moviemaking (!?) business
And why I'm already looking past yesterday's House hearing on PBMs
Plus the House Oversight Committee dropped its own PBM takedown ahead of today's hearing with PBM execs
And why 'CAA' is a candidate for abbreviation of the year
And GoodRx will make BI's Humira biosimilar available for $550
